The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

AML Hub Symposium | How does MRD impact outcome of stem cell transplantation in AML – now and in the future?

Mar 2, 2020

At the 46 thannual meeting of the European Society for Blood and Marrow Transplantation the AML Hub will hold a Satellite Symposium(March 22, 2020, 8:30 A.M., IFEMA – Feria de Madrid, ES) on the impact of measurable residual disease (MRD) on stem cell transplantation (SCT) outcome in patients with acute myeloid leukemia (AML). During this Satellite Symposium, five international experts, Gert Ossenkoppele, Jacqueline Cloos, Christian Thiede, Adriano Venditti, and Charles Craddock, will discuss the latest developments and remaining challenges of MRD assessments in the context of SCT. Here we present an introductory overview of the theme which will be explored in more depth at the Satellite Symposium.

With intensive chemotherapy, most patients with AML will be able to achieve a morphologic complete remission (mCR). However, the challenge is to keep those patients in remission, as without further treatment relapse occurs in the majority of them. Growing evidence suggests that MRD, defined as the presence of residual leukemic cells in bone marrow or peripheral blood in patients who achieved mCR, is a predictor of relapse and outcome. 1Determination of MRD is increasingly used to identify patients at high risk of relapse at an early time point and guide treatment decisions accordingly. 1,2

Despite its advantages, adoption of MRD assessments in standard clinical practice has been slow so far, partly due to a lack of standards regarding the use of various techniques, the source of cells and the best time-points for assessment, among others. In order to encourage the use of MRD and make it more accessible for clinical practice, the European LeukemiaNet (ELN) Working Party has recently provided guidelines to standardize approaches for MRD assessments in AML. 3

The most commonly used methods to detect MRD are multiparameter flow cytometry (MPFC) and real-time quantitative polymerase chain reaction (PCR; qPCR). Two other methods are emerging: digital PCR and next-generation sequencing. 3Each methodology has its advantages and disadvantages and needs to be standardized, validated, and improved to be used to guide clinical decision making.

Regarding the time-points for MPFC-based MRD assessment, the ELN recommends to assess before treatment and after consolidation therapy, but not much is known about the optimal time-points during follow-up. 3Many studies have demonstrated that MPFC-based MRD assessment has a prognostic value, with MRD-negativity associated with better outcomes. 4-7However, this technique is considered less sensitive compared to molecular techniques.

MRD assessment in the context of SCT

Evidence is accumulating that the presence of MRD assessed by MPFC immediately prior to allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a predictor of post-transplant outcomes in AML. 3Patients who are MRD-negative before transplant both in the ablative and non-myeloablative setting perform much better than those who are MRD-positive. 8Patients who are MRD-positive prior to allo-HSCT show higher relapse incidences and shorter survival, irrespective of the intensity of conditioning regimens or the used MRD marker. 9-13

However, results from the GIMEMA AML1310trial ( NCT01452646) showed that in patients with intermediate-risk AML, who were MRD-positive before transplant, allo-HSCT improved OS and disease-free survival (DFS) to comparable levels of patients in the “favorable-risk" group. These data demonstrated that despite the adverse prognostic effect shown for pre-allo-HSCT MRD-positive patients, allo-HSCT can improve outcomes.

Another study, the RELAZA2trial ( NCT01462578), tested the clinical benefit of MRD-guided treatment after allo-HSCT in patients with AML and myelodysplastic syndromes. In this trial, patients in CR after allo-HSCT who developed MRD-positive disease received pre-emptive azacitidine treatment. This intervention prevented overt morphological relapses in about half of the MRD-positive patients and delayed relapse in the other half. These findings demonstrate that MRD-guided treatment with a hypomethylating agent could be an effective strategy to prevent or delay relapse in patients with MRD-positive AML.


In recent years, a growing interest in MRD determination is raising and this is not surprising, since MRD assessments may help to inform prognosis and treatment decisions. A large number of published studies have shown that patients with MRD-positive AML are at higher risk of relapse and experience shorter OS compared to MRD-negative patients. Latest data from clinical studies provide exciting prospects for the use of MRD in a more personalized approach to allo-HSCT in patients with AML.

  1. Schwind S. et al.Use of minimal residual disease in acute myeloid leukemia therapy. Curr Treat Options Oncol. 2020 Jan 30; 21(1):8. DOI: 10.1007/s11864-019-0695-5
  2. Ossenkoppele G. et al.Can we incorporate MRD assessment into clinical practice in AML? Best Pract Res Clin Haematol. 2019 Jun; 32(2):186–191. DOI: 10.1016/j.beha.2019.05.003
  3. Schuurhuis G.J. et al. Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood.2018 Mar 22; 131(12):1275–1291. DOI: 10.1182/blood-2017-09-801498
  4. Terwijn M. et al.High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study. J Clin Oncol. 2013 Nov 1; 31(31):3889–97. DOI: 10.1200/JCO.2012.45.9628
  5. Freeman S.D. et al.Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia. J Clin Oncol. 2013 Nov 10; 31(32):4123–31. DOI: 10.1200/JCO.2013.49.1753
  6. Ravandi F. et al.Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia. Cancer.2017 Feb 1; 123(3):426–435. DOI: 10.1002/cncr.30361
  7. Freeman S.D. et al.Measurable residual disease at induction redefines partial response in acute myeloid leukemia and stratifies outcomes in patients at standard risk without NPM1 mutations. J Clin Oncol.2018 May 20; 36(15):1486–97. DOI: 10.1200/JCO.2017.76.3425
  8. Buckley S.A. et al.Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis. Haematologica.2017 May; 102(5):865–873. DOI: 10.3324/haematol.2016.159343
  9. Bill M. et al.Digital droplet PCR based absolute quantification of pre-transplant NPM1 mutation burden predicts relapse in acute myeloid leukemia patients. Ann Hematol.2018 Oct; 97(10):1757–1765. DOI: 10.1007/s00277-018-3373-y
  10. Jentzsch M. et al. High blood BAALC copy numbers at allogeneic transplantation predict early relapse in patients with acute myeloid leukemia. Oncotarget.2017 Sep 27; 8(50):87944–87954. DOI: 10.18632/oncotarget.21322
  11. Jentzsch M. et al. Prognostic impact of blood MN1 copy numbers before allogeneic stem cell transplantation in patients with acute myeloid leukemia. Hemasphere. 2019 Feb 8;3(1):e167. DOI: 10.1097/HS9.0000000000000167
  12. Thol F. et al.Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML. Blood.2018 Oct 18; 132(16):1703–1713. DOI: 10.1182/blood-2018-02-829911
  13. Appelbaum F.R.Hematopoietic cell transplantation as treatment of patients with acute myeloid leukemia with measurable residual disease after consolidation therapy. Best Pract Res Clin Haematol. 2018 Dec; 31(4):405–409 . DOI: 10.1016/j.beha.2018.09.009